Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | HPGD | P15428 | 4/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | HTR2C | P28335 | 1/20 | 0.46 |
| ▸ | HTR2B | P41595 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | TPMT | P51580 | 1/20 | 0.41 |
| ▸ | APEX1 | P27695 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14121949 | 0.87 | TDP1 (0.53) | TDP1CYP1A2GAACYP2C9PKM | |
| SCHEMBL14157664 | 0.83 | TDP1 (0.49) | TDP1CYP1A2GAACYP2C9PKM | |
| SCHEMBL8406844 | 0.82 | TDP1 (0.61) | TDP1CYP1A2GAACYP2C9PKM | |
| SCHEMBL20832771 | 0.82 | TDP1 (0.61) | TDP1CYP1A2GAACYP2C9PKM | |
| SCHEMBL30360591 | 0.82 | TDP1 (0.61) | TDP1CYP1A2GAACYP2C9PKM | |
| SCHEMBL1927200 | 0.82 | TDP1 (0.70) | TDP1CYP1A2GAACYP2C9PKM | |
| SCHEMBL11714089 | 0.80 | TDP1 (0.44) | TDP1CYP1A2GAACYP2C9PKM | |
| SCHEMBL1713795 | 0.79 | CYP1A2 (0.67) | TDP1CYP1A2GAACYP2C9PKM | |
| SCHEMBL4651678 | 0.79 | CYP1A2 (0.67) | TDP1CYP1A2GAACYP2C9PKM | |
| SCHEMBL7267831 | 0.79 | TPMT (0.41) | TDP1ALDH1A1HPGDTSHRKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118146176-B | GPR133/ADGRD1 agonist, preparation method and application thereof | 山东大学 | 2024-11-15 | — | — | CN | disclosed |
| CN-118146176-A | GPR133/ADGRD1 agonist, preparation method and application thereof | 山东大学 | 2024-06-07 | — | — | CN | disclosed |
| WO-2012170561-A1 | N-BENZYLINDOLE MODULATORS OF PPARG | THE SCRIPPS RESEARCH INSTITUTE (T.S.R.I.) (US) | 2012-12-13 | — | — | WO | disclosed |
| US-20050143423-A1 | Prodrugs of proton pump inhibitors background of the invention | GARST MICHAEL (US) | 2005-06-30 | — | — | US | disclosed |
| EP-0413839-A1 | GHRH analogs | The Administrators of The Tulane Educational Fund (US) | 1991-02-27 | — | — | EP | disclosed |
| US-4914189-A | STIMULATES RELEASE OF GROWTH HORMONE | THE ADMINSTRATORS OF THE TULANE EDUCATIONAL FUND (US) | 1990-04-03 | — | — | US | disclosed |
| EP-0277626-A2 | Synthetic GHRH analogs | The Administrators of The Tulane Educational Fund (US) | 1988-08-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050143423-A1 | Prodrugs of proton pump inhibitors background of the invention | ABCB11, SLC10A2, SI | TDP1 2288/4885CYP1A2 121/4885GAA 69/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.